Screening for bladder cancer: a perspective

[1]  W. See.  Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis , 2007 .

[2]  T. Cai,et al.  Long‐term outcome of hematuria home screening for bladder cancer in men , 2007, Cancer.

[3]  E. Messing,et al.  Long‐term outcome of hematuria home screening for bladder cancer in men , 2006, Cancer.

[4]  S. Johansson,et al.  Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. , 2006, The Journal of urology.

[5]  Y. Lotan,et al.  Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. , 2006, Urologic oncology.

[6]  Núria Malats,et al.  Smoking and Bladder Cancer in Spain: Effects of Tobacco Type, Timing, Environmental Tobacco Smoke, and Gender , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  D. Neal,et al.  Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. , 2006, Health technology assessment.

[8]  Y. Lotan,et al.  Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yair Lotan,et al.  Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy , 2005 .

[10]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[11]  N. Malats,et al.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses , 2005, The Lancet.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  E. Messing,et al.  Detection of bladder cancer using a point-of-care proteomic assay. , 2005, JAMA.

[14]  G. Gazelle,et al.  Cost-effectiveness of whole-body CT screening. , 2005, Radiology.

[15]  Giovanni Parmigiani,et al.  A Model-Based Comparison of Breast Cancer Screening Strategies: Mammograms and Clinical Breast Examinations , 2005, Cancer Epidemiology Biomarkers & Prevention.

[16]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[17]  M. Mehlman.  Predictive genetic testing in urology: ethical and social issues , 2004, World Journal of Urology.

[18]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[19]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[20]  Michael Pignone,et al.  Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[21]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Grönberg,et al.  A quantitative analysis of the costs and benefits of prostate cancer screening , 2001, Prostate Cancer and Prostatic Diseases.

[23]  E Dorant,et al.  The impact of characteristics of cigarette smoking on urinary tract cancer risk , 2000, Cancer.

[24]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer , 1999, European Urology.

[25]  M. Krahn,et al.  Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[26]  P. Whelan,et al.  Bladder tumours detected on screening: results at 7 years. , 1998, British journal of urology.

[27]  A R Willan,et al.  Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. J. Rosenquist,et al.  The cost-effectiveness of mammographic screening strategies. , 1995, JAMA.

[29]  E. Messing,et al.  Hematuria home screening: repeat testing results. , 1995, The Journal of urology.

[30]  E. Messing,et al.  Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. , 1995, Urology.

[31]  A. Dowell,et al.  A community study of bladder cancer screening by the detection of occult urinary bleeding. , 1992, The Journal of urology.